πŸ‡ΊπŸ‡Έ FDA
Patent

US 7982014

FGFR3-IIIc fusion proteins

granted A61KA61K45/06A61P

Quick answer

US patent 7982014 (FGFR3-IIIc fusion proteins) held by Five Prime Therapeutics, Inc. expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K45/06, A61P, A61P1/02, A61P1/04